Lake Street analyst Ryan Meyers raised the firm’s price target on Joint Corp. to $20 from $15 and keeps a Buy rating on the shares. In the near term, the firm thinks shares may remain range-bound as the company continues to progress through its corporate clinic transition and investors get a better understanding of the new model, but over the long term it thinks the strategy makes sense and believes the company will be able to create shareholder value.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JYNT: